Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BELLA study of relacorilant combinations in gynecological cancers
2024-517432-21-00Phase 2Authorised
- Sponsor
- Corcept Therapeutics
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, open-label trial of relacorilant in gynecological cancer, ovarian cancer, primary peritoneal cancer (PPC) and 2 more (3 arms), sponsored by Corcept Therapeutics. Primary endpoint: Progression-free survival. Planned start May 2025; status: authorised.
02
Drugs
relacorilant
03
Conditions
gynecological cancerovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)endometrial cancer (EC)
Beyond the preview
Go deeper on 2024-517432-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517432-21-00.